3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
42
Endocrine
42
Thoracic
6
Genitourinary
6
Gastrointestinal
6
CNS
6
Dermatologic
5
Sarcoma
4
Gynecologic
4
Lymphoid
3
Breast
3
NET
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Conditions
Neuroendocrine Tumors
169
Carcinoid Tumor
27
Carcinoma, Neuroendocrine
22
Neoplasms
16
Gastro-enteropancreatic neuroendocrine tumor
16
Adenoma, Islet Cell
15
Pancreatic Neoplasms
12
Neoplasm Metastasis
10
Pheochromocytoma
8
Paraganglioma
8
Sarcoma
7
Colorectal Neoplasms
7
Carcinoma
7
Neuroectodermal Tumors, Primitive
6
Neuroblastoma
6
Gastrointestinal Neoplasms
6
Vipoma
5
Somatostatinoma
5
Gastrinoma
5
Cholangiocarcinoma
5
Carcinoma, Islet Cell
5
Breast Neoplasms
5
Small Cell Lung Carcinoma
4
Serotonin Syndrome
4
Digestive System Neoplasms
4
Anus Neoplasms
4
Thyroid Neoplasms
3
Salivary Gland Neoplasms
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Interventions
entrectinib
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Thyroid Cancer, Papillary
×
NET
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts